REFERENCES
1. Trapp BD, Nave A K. Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci 2008;31:247-69.
3. Novartis Pharmaceuticals Corporation. GILENYA (fingolimod) Capsules: highlights of Prescribing Information; c2010. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022527s009lbl.pdf. [Last revised on 2014 Apr].
4. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O'Connor PW, Sandberg-Wollheim M, Thompson AJ, Weinshenker BG, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005;58:840-6.
5. Serono, Inc. Rebif (interferon beta-1a): U.S; License # 1574. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/ifnbser00203LB.pdf. [Last revised on 2003 May].
6. Kastalli S, El Aïdli S, Mourali S, Zaïem A, Daghfous R, Lakhal M. Cardiac arrhythmia induced by interferon beta-1a. Fundam Clin Pharmacol 2012;26:207-9.
7. Sonnenblick M, Rosin A. Cardiotoxicity of interferon. A review of 44 cases. Chest 1991;99:557-61.
8. El-Atrebi K, El-Bassyouni HT. Management of rare side effects of peginterferon and ribavirin therapy during hepatitis C treatment: a case report. Cases J 2009;2:7429.
9. Sasaki M, Sata M, Suzuki H, Tanikawa K. A case of chronic hepatitis C with sinus bradycardia during IFN therapy. Kurume Med J 1998;45:161-3.
10. Platanias LC, Uddin S, Colamonici OR. Tyrosine phosphorylation of the alpha and beta subunits of the type I interferon receptor. Interferon-beta selectively induces tyrosine phosphorylation of an alpha subunit-associated protein. J Biol Chem 1994;269:17761-4.
11. Ortaldo JR, Herberman RB, Harvey C, Osheroff P, Pan YC, Kelder B, Pestka S. A species of human alpha interferon that lacks the ability to boost human natural killer activity. Proc Natl Acad Sci U S A 1984;81:4926-9.